Proactive Investors - IQ-AI Ltd (LSE:LON:IQAI, OTCQB:IQAIF)’s wholly owned subsidiary Imaging Biometrics has had its handheld application IB Nimble selected by the Orthopedic Department of the Medical College of Wisconsin (MCW) for use in its treatment of bone metastases.
IB Nimble is used to track bone metastases while facilitating secure, virtual and real-time discussions among multidisciplinary treatment teams.
Designed initially by Dr Joseph Bovi, MD, professor of radiation oncology and neurosurgery at MCW, IB Nimble's base functionality has been enhanced to accommodate any disease or pathology that requires multidisciplinary input.
The clinical benefit of providing optimised treatments faster to patients with brain metastases is now being afforded to patients with bone mets.
"This marks the first installation for use in diseases sites other than brain metastases and demonstrates that IB Nimble is ready for widespread deployment," said Josh McComack, Imaging Biometrics’ director of software engineering.